ProShare Advisors LLC Buys 9,187 Shares of Accuray Incorporated (NASDAQ:ARAY)

ProShare Advisors LLC boosted its stake in shares of Accuray Incorporated (NASDAQ:ARAY) by 50.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 27,308 shares of the medical equipment provider’s stock after purchasing an additional 9,187 shares during the period. ProShare Advisors LLC’s holdings in Accuray were worth $54,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ARAY. Ameriprise Financial Inc. purchased a new stake in Accuray during the fourth quarter valued at approximately $35,000. Prudential Financial Inc. purchased a new stake in Accuray during the fourth quarter valued at approximately $43,000. Susquehanna Fundamental Investments LLC purchased a new stake in Accuray during the fourth quarter valued at approximately $66,000. Gabelli Funds LLC increased its holdings in Accuray by 12.5% during the fourth quarter. Gabelli Funds LLC now owns 45,000 shares of the medical equipment provider’s stock valued at $89,000 after buying an additional 5,000 shares during the last quarter. Finally, SG Americas Securities LLC increased its holdings in Accuray by 37.4% during the fourth quarter. SG Americas Securities LLC now owns 45,079 shares of the medical equipment provider’s stock valued at $89,000 after buying an additional 12,259 shares during the last quarter. Institutional investors own 64.08% of the company’s stock.

Accuray Stock Up 1.3%

Shares of ARAY stock opened at $1.57 on Wednesday. Accuray Incorporated has a 12 month low of $1.28 and a 12 month high of $2.95. The stock has a market cap of $161.73 million, a P/E ratio of -31.40 and a beta of 1.30. The company has a current ratio of 1.62, a quick ratio of 0.88 and a debt-to-equity ratio of 3.51. The company has a 50 day simple moving average of $1.56 and a two-hundred day simple moving average of $1.88.

Accuray (NASDAQ:ARAY) last announced its quarterly earnings data on Wednesday, April 30th. The medical equipment provider reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.04. The firm had revenue of $113.24 million during the quarter, compared to analysts’ expectations of $101.53 million. Accuray had a negative net margin of 0.96% and a negative return on equity of 9.75%. On average, research analysts expect that Accuray Incorporated will post 0.01 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised shares of Accuray from a “hold” rating to a “buy” rating in a report on Friday, May 30th.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.